Generation of Potent Cytotoxic T Lymphocytes Against Castration‐Resistant Prostate Cancer Cells by Dendritic Cells Loaded With Dying Allogeneic Prostate Cancer Cells

To induce a potent cytotoxic T lymphocyte (CTL) response in dendritic cell (DC)‐based immunotherapy against prostate cancer, various tumour antigens should be loaded onto DCs. The aim of this study was to establish a method of immunotherapy for castration‐resistant prostate cancer (CRPC) using prost...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scandinavian journal of immunology 2013-02, Vol.77 (2), p.117-124
Hauptverfasser: Hwang, E. C., Lim, M.‐S., Im, C.‐M., Kwon, D.‐D., Lee, H.‐J., Nguyen‐Pham, T.‐N., Lee, Y.‐K., Lee, J.‐J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 124
container_issue 2
container_start_page 117
container_title Scandinavian journal of immunology
container_volume 77
creator Hwang, E. C.
Lim, M.‐S.
Im, C.‐M.
Kwon, D.‐D.
Lee, H.‐J.
Nguyen‐Pham, T.‐N.
Lee, Y.‐K.
Lee, J.‐J.
description To induce a potent cytotoxic T lymphocyte (CTL) response in dendritic cell (DC)‐based immunotherapy against prostate cancer, various tumour antigens should be loaded onto DCs. The aim of this study was to establish a method of immunotherapy for castration‐resistant prostate cancer (CRPC) using prostate cancer–specific CTLs generated in vitro by DCs. Monocyte‐derived DCs from patients with CRPC were induced to mature using a standard cytokine cocktail (in IL‐1β, TNF‐α, IL‐6 and PGE2: standard DCs, sDCs) or using an α‐type 1‐polarized DC (αDC1) cocktail (in IL‐1β, TNF‐α, IFN‐α, IFN‐γ and polyinosinic:polycytidylic acid) and loaded with the UVB‐irradiated CRPC cell line PC‐3. Antigen‐loaded DCs were evaluated by morphological and functional assays. The αDC1s significantly increased the expression of several molecules related to DC maturation, regardless of whether the αDC1s were loaded with tumour antigens or not, compared to sDCs. The αDC1s showed a higher production of interleukin‐12 both during maturation and after subsequent stimulation with CD40L, which was not significantly affected by loading with tumour antigens, as compared to standard DCs (sDCs). Prostate cancer–specific CTLs against autologous CRPC cells were successfully induced by αDC1s loaded with dying PC‐3 cells. Autologous αDC1s loaded with an allogeneic CRPC cell line can generate greater CRPC‐specific CTL responses as compared to sDCs and may provide a novel source of DC‐based vaccines that can be used for the development of immunotherapy in patients with CRPC.
doi_str_mv 10.1111/sji.12007
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1315622687</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1282042520</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4217-7969048d7d9b16af4718f57dd15a1c407fef31ff5941362d9fa568b986a7f24f3</originalsourceid><addsrcrecordid>eNqFkU9uEzEUhy0EoqGw4ALIEhtYTOv_nllGKZSiSK2giKXljO3U0cRObUcwO47ALbgXJ6nLFBaoCG9s-X3-9Px-ADzH6AjXdZw3_ggThOQDMMNU8Iailj4EM0QRajom-QF4kvMGIUyJpI_BAaGYCE7FDPw4tcEmXXwMMDp4EYsNBS7GEkv86nt4CZfjdncV-7HYDOdr7UOudZ3L9Ojnt-8fbPa56PrsIsV6KLbWQ28TXNhhyHA1whMbTPKl-qarZdTGGvjZlyt4MvqwhvNhiOvaSkXutTwFj5wesn12tx-CT2_fXC7eNcvz07PFfNn0jGDZyE50iLVGmm6FhXZM4tZxaQzmGvcMSWcdxc7xjtVBEdM5zUW76lqhpSPM0UPwavLuUrze21zU1ue-dqCDjfusMMVcECJa-X-UtAQxwgmq6Mu_0E3cp1A_ojCjpEbXibZSryeqrxPIyTq1S36r06gwUrdBqxq0-hV0ZV_cGferrTV_yN_JVuB4Ar74wY7_NqmP788m5Q0v7LO5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1432200968</pqid></control><display><type>article</type><title>Generation of Potent Cytotoxic T Lymphocytes Against Castration‐Resistant Prostate Cancer Cells by Dendritic Cells Loaded With Dying Allogeneic Prostate Cancer Cells</title><source>MEDLINE</source><source>Wiley Online Library Free Content</source><source>Access via Wiley Online Library</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Hwang, E. C. ; Lim, M.‐S. ; Im, C.‐M. ; Kwon, D.‐D. ; Lee, H.‐J. ; Nguyen‐Pham, T.‐N. ; Lee, Y.‐K. ; Lee, J.‐J.</creator><creatorcontrib>Hwang, E. C. ; Lim, M.‐S. ; Im, C.‐M. ; Kwon, D.‐D. ; Lee, H.‐J. ; Nguyen‐Pham, T.‐N. ; Lee, Y.‐K. ; Lee, J.‐J.</creatorcontrib><description>To induce a potent cytotoxic T lymphocyte (CTL) response in dendritic cell (DC)‐based immunotherapy against prostate cancer, various tumour antigens should be loaded onto DCs. The aim of this study was to establish a method of immunotherapy for castration‐resistant prostate cancer (CRPC) using prostate cancer–specific CTLs generated in vitro by DCs. Monocyte‐derived DCs from patients with CRPC were induced to mature using a standard cytokine cocktail (in IL‐1β, TNF‐α, IL‐6 and PGE2: standard DCs, sDCs) or using an α‐type 1‐polarized DC (αDC1) cocktail (in IL‐1β, TNF‐α, IFN‐α, IFN‐γ and polyinosinic:polycytidylic acid) and loaded with the UVB‐irradiated CRPC cell line PC‐3. Antigen‐loaded DCs were evaluated by morphological and functional assays. The αDC1s significantly increased the expression of several molecules related to DC maturation, regardless of whether the αDC1s were loaded with tumour antigens or not, compared to sDCs. The αDC1s showed a higher production of interleukin‐12 both during maturation and after subsequent stimulation with CD40L, which was not significantly affected by loading with tumour antigens, as compared to standard DCs (sDCs). Prostate cancer–specific CTLs against autologous CRPC cells were successfully induced by αDC1s loaded with dying PC‐3 cells. Autologous αDC1s loaded with an allogeneic CRPC cell line can generate greater CRPC‐specific CTL responses as compared to sDCs and may provide a novel source of DC‐based vaccines that can be used for the development of immunotherapy in patients with CRPC.</description><identifier>ISSN: 0300-9475</identifier><identifier>EISSN: 1365-3083</identifier><identifier>DOI: 10.1111/sji.12007</identifier><identifier>PMID: 23126536</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>alpha -Interferon ; Antigens, Neoplasm - immunology ; Antigens, Neoplasm - metabolism ; Cancer Vaccines ; Castration ; CD40L protein ; Cell Line, Tumor ; Cytotoxicity ; Dendritic cells ; Dendritic Cells - immunology ; Dendritic Cells - metabolism ; Epitopes, T-Lymphocyte - immunology ; gamma -Interferon ; Humans ; Immunotherapy ; Interleukin 1 ; Interleukin 12 ; Interleukin 6 ; Interleukin-12 - biosynthesis ; Lymphocytes T ; Male ; Monocytes ; Prostaglandin E2 ; Prostate cancer ; Prostatic Neoplasms - immunology ; T-Lymphocytes, Cytotoxic - immunology ; Tumor necrosis factor- alpha ; Vaccines</subject><ispartof>Scandinavian journal of immunology, 2013-02, Vol.77 (2), p.117-124</ispartof><rights>2012 The Authors. Scandinavian Journal of Immunology © 2012 Blackwell Publishing Ltd</rights><rights>2012 The Authors. Scandinavian Journal of Immunology © 2012 Blackwell Publishing Ltd.</rights><rights>Scandinavian Journal of Immunology © 2013 Blackwell Publishing Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4217-7969048d7d9b16af4718f57dd15a1c407fef31ff5941362d9fa568b986a7f24f3</citedby><cites>FETCH-LOGICAL-c4217-7969048d7d9b16af4718f57dd15a1c407fef31ff5941362d9fa568b986a7f24f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fsji.12007$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fsji.12007$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23126536$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hwang, E. C.</creatorcontrib><creatorcontrib>Lim, M.‐S.</creatorcontrib><creatorcontrib>Im, C.‐M.</creatorcontrib><creatorcontrib>Kwon, D.‐D.</creatorcontrib><creatorcontrib>Lee, H.‐J.</creatorcontrib><creatorcontrib>Nguyen‐Pham, T.‐N.</creatorcontrib><creatorcontrib>Lee, Y.‐K.</creatorcontrib><creatorcontrib>Lee, J.‐J.</creatorcontrib><title>Generation of Potent Cytotoxic T Lymphocytes Against Castration‐Resistant Prostate Cancer Cells by Dendritic Cells Loaded With Dying Allogeneic Prostate Cancer Cells</title><title>Scandinavian journal of immunology</title><addtitle>Scand J Immunol</addtitle><description>To induce a potent cytotoxic T lymphocyte (CTL) response in dendritic cell (DC)‐based immunotherapy against prostate cancer, various tumour antigens should be loaded onto DCs. The aim of this study was to establish a method of immunotherapy for castration‐resistant prostate cancer (CRPC) using prostate cancer–specific CTLs generated in vitro by DCs. Monocyte‐derived DCs from patients with CRPC were induced to mature using a standard cytokine cocktail (in IL‐1β, TNF‐α, IL‐6 and PGE2: standard DCs, sDCs) or using an α‐type 1‐polarized DC (αDC1) cocktail (in IL‐1β, TNF‐α, IFN‐α, IFN‐γ and polyinosinic:polycytidylic acid) and loaded with the UVB‐irradiated CRPC cell line PC‐3. Antigen‐loaded DCs were evaluated by morphological and functional assays. The αDC1s significantly increased the expression of several molecules related to DC maturation, regardless of whether the αDC1s were loaded with tumour antigens or not, compared to sDCs. The αDC1s showed a higher production of interleukin‐12 both during maturation and after subsequent stimulation with CD40L, which was not significantly affected by loading with tumour antigens, as compared to standard DCs (sDCs). Prostate cancer–specific CTLs against autologous CRPC cells were successfully induced by αDC1s loaded with dying PC‐3 cells. Autologous αDC1s loaded with an allogeneic CRPC cell line can generate greater CRPC‐specific CTL responses as compared to sDCs and may provide a novel source of DC‐based vaccines that can be used for the development of immunotherapy in patients with CRPC.</description><subject>alpha -Interferon</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Antigens, Neoplasm - metabolism</subject><subject>Cancer Vaccines</subject><subject>Castration</subject><subject>CD40L protein</subject><subject>Cell Line, Tumor</subject><subject>Cytotoxicity</subject><subject>Dendritic cells</subject><subject>Dendritic Cells - immunology</subject><subject>Dendritic Cells - metabolism</subject><subject>Epitopes, T-Lymphocyte - immunology</subject><subject>gamma -Interferon</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Interleukin 1</subject><subject>Interleukin 12</subject><subject>Interleukin 6</subject><subject>Interleukin-12 - biosynthesis</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Monocytes</subject><subject>Prostaglandin E2</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - immunology</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Tumor necrosis factor- alpha</subject><subject>Vaccines</subject><issn>0300-9475</issn><issn>1365-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9uEzEUhy0EoqGw4ALIEhtYTOv_nllGKZSiSK2giKXljO3U0cRObUcwO47ALbgXJ6nLFBaoCG9s-X3-9Px-ADzH6AjXdZw3_ggThOQDMMNU8Iailj4EM0QRajom-QF4kvMGIUyJpI_BAaGYCE7FDPw4tcEmXXwMMDp4EYsNBS7GEkv86nt4CZfjdncV-7HYDOdr7UOudZ3L9Ojnt-8fbPa56PrsIsV6KLbWQ28TXNhhyHA1whMbTPKl-qarZdTGGvjZlyt4MvqwhvNhiOvaSkXutTwFj5wesn12tx-CT2_fXC7eNcvz07PFfNn0jGDZyE50iLVGmm6FhXZM4tZxaQzmGvcMSWcdxc7xjtVBEdM5zUW76lqhpSPM0UPwavLuUrze21zU1ue-dqCDjfusMMVcECJa-X-UtAQxwgmq6Mu_0E3cp1A_ojCjpEbXibZSryeqrxPIyTq1S36r06gwUrdBqxq0-hV0ZV_cGferrTV_yN_JVuB4Ar74wY7_NqmP788m5Q0v7LO5</recordid><startdate>201302</startdate><enddate>201302</enddate><creator>Hwang, E. C.</creator><creator>Lim, M.‐S.</creator><creator>Im, C.‐M.</creator><creator>Kwon, D.‐D.</creator><creator>Lee, H.‐J.</creator><creator>Nguyen‐Pham, T.‐N.</creator><creator>Lee, Y.‐K.</creator><creator>Lee, J.‐J.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201302</creationdate><title>Generation of Potent Cytotoxic T Lymphocytes Against Castration‐Resistant Prostate Cancer Cells by Dendritic Cells Loaded With Dying Allogeneic Prostate Cancer Cells</title><author>Hwang, E. C. ; Lim, M.‐S. ; Im, C.‐M. ; Kwon, D.‐D. ; Lee, H.‐J. ; Nguyen‐Pham, T.‐N. ; Lee, Y.‐K. ; Lee, J.‐J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4217-7969048d7d9b16af4718f57dd15a1c407fef31ff5941362d9fa568b986a7f24f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>alpha -Interferon</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Antigens, Neoplasm - metabolism</topic><topic>Cancer Vaccines</topic><topic>Castration</topic><topic>CD40L protein</topic><topic>Cell Line, Tumor</topic><topic>Cytotoxicity</topic><topic>Dendritic cells</topic><topic>Dendritic Cells - immunology</topic><topic>Dendritic Cells - metabolism</topic><topic>Epitopes, T-Lymphocyte - immunology</topic><topic>gamma -Interferon</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Interleukin 1</topic><topic>Interleukin 12</topic><topic>Interleukin 6</topic><topic>Interleukin-12 - biosynthesis</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Monocytes</topic><topic>Prostaglandin E2</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - immunology</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Tumor necrosis factor- alpha</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hwang, E. C.</creatorcontrib><creatorcontrib>Lim, M.‐S.</creatorcontrib><creatorcontrib>Im, C.‐M.</creatorcontrib><creatorcontrib>Kwon, D.‐D.</creatorcontrib><creatorcontrib>Lee, H.‐J.</creatorcontrib><creatorcontrib>Nguyen‐Pham, T.‐N.</creatorcontrib><creatorcontrib>Lee, Y.‐K.</creatorcontrib><creatorcontrib>Lee, J.‐J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Scandinavian journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hwang, E. C.</au><au>Lim, M.‐S.</au><au>Im, C.‐M.</au><au>Kwon, D.‐D.</au><au>Lee, H.‐J.</au><au>Nguyen‐Pham, T.‐N.</au><au>Lee, Y.‐K.</au><au>Lee, J.‐J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Generation of Potent Cytotoxic T Lymphocytes Against Castration‐Resistant Prostate Cancer Cells by Dendritic Cells Loaded With Dying Allogeneic Prostate Cancer Cells</atitle><jtitle>Scandinavian journal of immunology</jtitle><addtitle>Scand J Immunol</addtitle><date>2013-02</date><risdate>2013</risdate><volume>77</volume><issue>2</issue><spage>117</spage><epage>124</epage><pages>117-124</pages><issn>0300-9475</issn><eissn>1365-3083</eissn><abstract>To induce a potent cytotoxic T lymphocyte (CTL) response in dendritic cell (DC)‐based immunotherapy against prostate cancer, various tumour antigens should be loaded onto DCs. The aim of this study was to establish a method of immunotherapy for castration‐resistant prostate cancer (CRPC) using prostate cancer–specific CTLs generated in vitro by DCs. Monocyte‐derived DCs from patients with CRPC were induced to mature using a standard cytokine cocktail (in IL‐1β, TNF‐α, IL‐6 and PGE2: standard DCs, sDCs) or using an α‐type 1‐polarized DC (αDC1) cocktail (in IL‐1β, TNF‐α, IFN‐α, IFN‐γ and polyinosinic:polycytidylic acid) and loaded with the UVB‐irradiated CRPC cell line PC‐3. Antigen‐loaded DCs were evaluated by morphological and functional assays. The αDC1s significantly increased the expression of several molecules related to DC maturation, regardless of whether the αDC1s were loaded with tumour antigens or not, compared to sDCs. The αDC1s showed a higher production of interleukin‐12 both during maturation and after subsequent stimulation with CD40L, which was not significantly affected by loading with tumour antigens, as compared to standard DCs (sDCs). Prostate cancer–specific CTLs against autologous CRPC cells were successfully induced by αDC1s loaded with dying PC‐3 cells. Autologous αDC1s loaded with an allogeneic CRPC cell line can generate greater CRPC‐specific CTL responses as compared to sDCs and may provide a novel source of DC‐based vaccines that can be used for the development of immunotherapy in patients with CRPC.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>23126536</pmid><doi>10.1111/sji.12007</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0300-9475
ispartof Scandinavian journal of immunology, 2013-02, Vol.77 (2), p.117-124
issn 0300-9475
1365-3083
language eng
recordid cdi_proquest_miscellaneous_1315622687
source MEDLINE; Wiley Online Library Free Content; Access via Wiley Online Library; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals
subjects alpha -Interferon
Antigens, Neoplasm - immunology
Antigens, Neoplasm - metabolism
Cancer Vaccines
Castration
CD40L protein
Cell Line, Tumor
Cytotoxicity
Dendritic cells
Dendritic Cells - immunology
Dendritic Cells - metabolism
Epitopes, T-Lymphocyte - immunology
gamma -Interferon
Humans
Immunotherapy
Interleukin 1
Interleukin 12
Interleukin 6
Interleukin-12 - biosynthesis
Lymphocytes T
Male
Monocytes
Prostaglandin E2
Prostate cancer
Prostatic Neoplasms - immunology
T-Lymphocytes, Cytotoxic - immunology
Tumor necrosis factor- alpha
Vaccines
title Generation of Potent Cytotoxic T Lymphocytes Against Castration‐Resistant Prostate Cancer Cells by Dendritic Cells Loaded With Dying Allogeneic Prostate Cancer Cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T11%3A02%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Generation%20of%20Potent%20Cytotoxic%20T%20Lymphocytes%20Against%20Castration%E2%80%90Resistant%20Prostate%20Cancer%20Cells%20by%20Dendritic%20Cells%20Loaded%20With%20Dying%20Allogeneic%20Prostate%20Cancer%20Cells&rft.jtitle=Scandinavian%20journal%20of%20immunology&rft.au=Hwang,%20E.%20C.&rft.date=2013-02&rft.volume=77&rft.issue=2&rft.spage=117&rft.epage=124&rft.pages=117-124&rft.issn=0300-9475&rft.eissn=1365-3083&rft_id=info:doi/10.1111/sji.12007&rft_dat=%3Cproquest_cross%3E1282042520%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1432200968&rft_id=info:pmid/23126536&rfr_iscdi=true